EGFR and head and neck squamous cell carcinoma: The approval of the epidermal growth factor-receptor (EGFR) antagonist cetuximab introduced the first targeted therapy in SCCHN showing increased locoregional control when compared to RT alone [7] and improved outcome when combined with chemotherapy in the palliative situation [8].